The future of immunotherapy in prostate cancer

Charles G. Drake

Research output: Contribution to journalArticle

Abstract

Two active immunotherapy approaches for prostate cancer have progressed to phase III trials that are either completed (sipuleucel-T) or ongoing (GVAX). Published data on a completed trial of sipuleucel-T report a significant survival benefit[23]-a notable first for the field. Future immunotherapy approaches for prostate cancer will almost certainly combine active immunotherapy with either antitumor monoclonal antibodies or with coinhibitor blockade to augment efficacy. As discussed above, the area of specific antigen identification remains relatively open, providing encouragement for the development of more directed targeting approaches. Finally, it is worth noting that a large number of diverse active immunotherapy approaches are in active clinical and preclinical development. These include DNA vectors,[24] attenuated viral vectors,[25] loaded dendritic cells,[26] and novel vectors based on attenuated bacterial vectors.[27] Taken together, these observations con-firm Dr. Slovin's assertion that immunotherapy is likely to emerge as a viable treatment option for patients with prostate cancer.

Original languageEnglish (US)
JournalOncology
Volume21
Issue number3
StatePublished - Mar 2007

Fingerprint

Active Immunotherapy
Immunotherapy
Prostatic Neoplasms
Dendritic Cells
Monoclonal Antibodies
Antigens
Survival
DNA
sipuleucel-T
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

The future of immunotherapy in prostate cancer. / Drake, Charles G.

In: Oncology, Vol. 21, No. 3, 03.2007.

Research output: Contribution to journalArticle

Drake, CG 2007, 'The future of immunotherapy in prostate cancer', Oncology, vol. 21, no. 3.
Drake, Charles G. / The future of immunotherapy in prostate cancer. In: Oncology. 2007 ; Vol. 21, No. 3.
@article{1e6f935a68a64228a0915163ce0d3945,
title = "The future of immunotherapy in prostate cancer",
abstract = "Two active immunotherapy approaches for prostate cancer have progressed to phase III trials that are either completed (sipuleucel-T) or ongoing (GVAX). Published data on a completed trial of sipuleucel-T report a significant survival benefit[23]-a notable first for the field. Future immunotherapy approaches for prostate cancer will almost certainly combine active immunotherapy with either antitumor monoclonal antibodies or with coinhibitor blockade to augment efficacy. As discussed above, the area of specific antigen identification remains relatively open, providing encouragement for the development of more directed targeting approaches. Finally, it is worth noting that a large number of diverse active immunotherapy approaches are in active clinical and preclinical development. These include DNA vectors,[24] attenuated viral vectors,[25] loaded dendritic cells,[26] and novel vectors based on attenuated bacterial vectors.[27] Taken together, these observations con-firm Dr. Slovin's assertion that immunotherapy is likely to emerge as a viable treatment option for patients with prostate cancer.",
author = "Drake, {Charles G.}",
year = "2007",
month = "3",
language = "English (US)",
volume = "21",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "3",

}

TY - JOUR

T1 - The future of immunotherapy in prostate cancer

AU - Drake, Charles G.

PY - 2007/3

Y1 - 2007/3

N2 - Two active immunotherapy approaches for prostate cancer have progressed to phase III trials that are either completed (sipuleucel-T) or ongoing (GVAX). Published data on a completed trial of sipuleucel-T report a significant survival benefit[23]-a notable first for the field. Future immunotherapy approaches for prostate cancer will almost certainly combine active immunotherapy with either antitumor monoclonal antibodies or with coinhibitor blockade to augment efficacy. As discussed above, the area of specific antigen identification remains relatively open, providing encouragement for the development of more directed targeting approaches. Finally, it is worth noting that a large number of diverse active immunotherapy approaches are in active clinical and preclinical development. These include DNA vectors,[24] attenuated viral vectors,[25] loaded dendritic cells,[26] and novel vectors based on attenuated bacterial vectors.[27] Taken together, these observations con-firm Dr. Slovin's assertion that immunotherapy is likely to emerge as a viable treatment option for patients with prostate cancer.

AB - Two active immunotherapy approaches for prostate cancer have progressed to phase III trials that are either completed (sipuleucel-T) or ongoing (GVAX). Published data on a completed trial of sipuleucel-T report a significant survival benefit[23]-a notable first for the field. Future immunotherapy approaches for prostate cancer will almost certainly combine active immunotherapy with either antitumor monoclonal antibodies or with coinhibitor blockade to augment efficacy. As discussed above, the area of specific antigen identification remains relatively open, providing encouragement for the development of more directed targeting approaches. Finally, it is worth noting that a large number of diverse active immunotherapy approaches are in active clinical and preclinical development. These include DNA vectors,[24] attenuated viral vectors,[25] loaded dendritic cells,[26] and novel vectors based on attenuated bacterial vectors.[27] Taken together, these observations con-firm Dr. Slovin's assertion that immunotherapy is likely to emerge as a viable treatment option for patients with prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=33947581263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947581263&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33947581263

VL - 21

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 3

ER -